

CLOs

The Tail of CQTs: Return of the Repricings

| CORE

As loan repricings increase and downgrade rates remain high, CLO collateral quality tests are at risk of more failures. However, the pain should be felt unevenly across deals, with managers most exposed to the tails of the loan market (“barbelling”) seeing more pressure on tests and the potential need to slowly de-risk.

Geoffrey Horton, CFA
+44 (0) 20 3134 2680
geoffrey.horton@barclays.com
Barclays, UK

This report was previously published in the [European Credit Alpha](#), January 31, 2020.

With loan repricing supply taking off in the US (see [Reprice If the Price is Right](#)) and Europe (see [Rally On, Reprice More](#)), concerns about the effects of repricings on CLOs have increased. The caution is understandable: following the last loan market repricing wave in 2016, weighted average spread (WAS) test failure rates increased to 8-13% from close to zero and annualized median equity distributions fell 7-10 points.

This time around, though, we expect limited downside to average loan index coupons based on current coupon saving levels for loans. But while the average coupon should see limited decline, the tails of the loan market could see larger changes. In combination with heightened loan downgrades, managers that utilize a barbell strategy could see collateral quality test (CQT) failures increase relatively more, with excess spread also declining, pushing equity distributions lower.

Manager Deep Dive

The increase in loan repricings was just another example of the challenges CLO managers faced in 2019. Loan downgrade to upgrade ratios were the highest in years, with downside moves after a downgrade growing more violent (see [Be Careful of Falling B's](#)). With weighted average rating factors (WARFs) moving higher as a result, and now WAS, which has remained relatively flat hitherto, potentially coming under pressure, CLO managers have had to become more creative to keep passing CQTs (see [Global CLO Primer](#) for an explanation of CQTs).

To better understand the effects of the loan repricings and downgrades on the CLO market, we analyzed changes in CLO managers' portfolios from September 1, 2019, to January 27, 2020. We used the set of CLO managers that had at least two CLOs in reinvestment as of January 27, 2020,

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242. Barclays trades the securities covered in this report for its own account and on a discretionary basis on behalf of certain clients. Such trading interests may be contrary to the recommendations offered in this report.

Please see analyst certifications and important disclosures beginning on page 11 .

Completed: 30-Jan-20, 21:49 GMT Released: 31-Jan-20, 11:30 GMT Restricted - External

with original settle dates between January 1, 2010, and March 27, 2019. This analysis encompasses 101 US BSL and 36 European CLO managers; the manager data can be found in the Excel attachment to this report.

CLO Manager Data

Backup US BSL and European CLO manager data utilized throughout the report


Asset Coupon Transitions

As noted in our 2020 US Loan Outlook (see [Enthusiasm curbed by tail risks](#)), we expect the effect of repricings on the index to be less than 10bp this year (with similar results in Europe), but segmented spread buckets are likely to see different levels of spread compression as the percentage of assets trading above par is skewed towards higher rated, lower spread assets.

As [Figure 1](#) shows, around 75% of loans in US BSL CLOs with a spread below 300bp (31% of CLO assets) trade above par, while only about half of loans with spreads between 300bp and 400bp trade above par (38% of assets). The percentage of higher spread loans is even lower - just 33% of loans with a spread of 450bp or more (18% of assets) are trading above par.


The buckets of assets trading above par are even larger in European CLOs ([Figure 2](#)). Roughly 79% of assets with a coupon below 300bp (11% of CLO assets) are trading above par, while more than 60% of assets with coupons between 300bp and 400bp trade above par (54% of assets). Similar to the US, though, the percentage of higher coupon assets is lower - just 39% of assets with a coupon of 450bp or more (18% of assets) are trading above par.

FIGURE 1. Lower Spread Assets in US CLOs Are More Likely to Trade above Par



Note: Assets in reinvestment US BSL CLOs
Source: Kanerai, Intex, Markit, Barclays Research


FIGURE 2. Similar Story for Assets in European CLOs, Though Percentages Are Higher in Comparison




Note: Assets in reinvestment European CLOs
Source: Kanerai, Intex, Markit, Barclays Research

With assets that have lower coupons more likely to trade above par, we would expect to see these buckets in CLOs (generally less than 400bp of spread) decline relatively more should repricings continue and managers attempt to maintain WAS test cushion. Already, US BSL CLO managers have reduced exposure to loans with spreads between 300bp and 350bp by 2.2 percentage points since the start of September, while exposure to higher spread loans has increased 1.4 percentage points ([Figure 3](#)).

European CLOs saw a nearly opposite trend, though, with exposure to assets with coupons between 300bp and 400bp increasing 0.6 to 1.0 percentage point since September, but exposure to assets with a coupon below 300bp and assets with coupons of 400bp or higher falling ([Figure 4](#)).


FIGURE 3. Exposure to Lower Spread Assets Has Declined in US CLOs

Note: Only US CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanera, Intex, Barclays Research


FIGURE 4. Opposite for European CLOs, with Higher Coupon Asset Buckets Seeing the Largest Decrease in Exposure

Note: Only European CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanera, Intex, Barclays Research

Repositioning in the tails of asset spreads drove most of the change in US BSL CLO WAS, with changes in exposure to assets paying 450bp or more driving a majority of the change (Figure 5). For the 25 managers that outperformed in WAS change over the roughly four-month period, asset spread exposure was reallocated from lower spread buckets (300-400bp) into assets with spreads of 450bp or more (Figure 6).


FIGURE 5. The Tails of Asset Spreads Drove the Change in US CLO WAS

Only US CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanera, Intex, Barclays Research


FIGURE 6. Deals That Outperformed in WAS Change Did So by Reallocating to Higher-Spread Buckets

Note: Only US CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanera, Intex, Barclays Research

Similar to the US, repositioning of the tails of asset coupons drove most of the change in European CLO weighted average coupons (WAC), with changes in exposure to assets paying 450bp or more a bigger driver than in the US (Figure 7). For the 10 managers that saw the most WAC underperformance, exposure was reallocated from higher coupon buckets (400bp or more) into assets with coupons of less than 400bp (Figure 8).

FIGURE 7. The Tails of Asset Coupons Drove Even More of the Change in WAC for European CLOs

Note: Only European CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanera, Intex, Barclays Research


FIGURE 8. Deals That Outperformed in WAC Change Did So by Reallocating to Higher-Spread Buckets

Note: Only European CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanera, Intex, Barclays Research


Looking Back

The last repricing wave in the US and European loan markets also drove significant changes to CLO portfolio compositions, with asset spreads declining materially for more than two years. From January 2016 to January 2018, the median US BSL CLO WAS declined over 90bp, with the median European CLO WAS falling nearly 70bp. As a result, CLO WAS tests began to fail. While a manager can still typically trade the portfolio if a CQT fails, the following purchases must maintain or improve the failing test, which can be difficult in an environment where most assets are repricing lower.

In the US, 13% of in reinvestment US BSL CLOs were failing their WAS test by mid-2018, with more than 40% having 5bp or less of WAS test cushion (Figure 9). European CLOs saw relatively fewer WAS test failures, reaching a max of only 8% and with just over 30% having 5bp or less of test cushion at the peak (Figure 10).

FIGURE 9. WAS Failure Rates Reached 13% in US BSL CLOs Following the Last Repricing Wave...

Note: Only in reinvestment US BSL CLOs.
Source: Kanera, Intex, Barclays Research


FIGURE 10. ...While WAS Failure Rates Reached Only 8% in Europe

Note: Only in reinvestment European CLOs.
Source: Kanera, Intex, Barclays Research

An increase in CQT failure rates was not the only by-product of the last repricing wave; excess spread also declined sharply, pushing CLO equity distributions lower. Median annualized equity distributions for US BSL CLOs fell from around 21% at the start of 2016 to around 11% by the


start of 2018 (Figure 11), and from around 20% down to 13%, respectively, for European CLOs (Figure 12).

FIGURE 11. US CLO Annualized Equity Distributions Fell by around Ten Points from 2016 to 2018



Note: Median equity distributions for all in reinvestment US BSL CLOs.
Source: Kanerai, Intex, Barclays Research

FIGURE 12. European CLO Annualized Equity Distributions Fell by Only around Seven Points



Note: Median equity distributions for all in reinvestment European CLOs.
Source: Kanerai, Intex, Barclays Research


A continued surge in repricings could not only pressure excess spread, but may also put pressure on new issue CLO supply if CLO liability costs do not decrease in line with asset spreads to help the equity arb (ie. the difference between CLO asset spreads and debt cost). However, as we noted in [Reprice If the Price is Right](#), we do not think it is worth lowering our issuance forecasts since the effect on CLO assets should be relatively capped. Additionally, there are many more factors to the equity arb than just the spread on the assets, as we discussed in [Dissecting and Forecasting the CLO Equity Arb](#).

Asset Rating Transitions

Rating transition concerns also continue to be elevated, especially as downgrades remain heightened and higher rated assets are being repriced. While asset ratings in CLOs typically center around the single-B category, assets with a facility rating of Ba or higher still typically account for a fourth to a third of collateral in US BSL CLOs.


Around 70% of the Ba rated in assets in US CLOs are trading above par, while this falls to only half for B1 assets (Figure 13). Lower-rated assets are trading lower: just 38% and 22% of B2 and B3 assets are trading above par, respectively.

While B1 and higher exposure in European CLOs is typically lower by comparison at only 10-15% of collateral, higher-rated assets are still trading higher. More than 80% of the Ba and B1 rated in assets in European CLOs trade above par, while only about half of B2 rated assets and 33% of B3 assets are trading above par (Figure 14).

FIGURE 13. Higher-Rated Assets in US CLOs Are More Likely to Trade above Par

Note: Assets in reinvestment US BSL CLOs.


Source: Kanerai, Intex, Markit, Barclays Research

FIGURE 14. Similar for European CLO Assets, Though Percentages Are Generally Higher in comparison

Note: Assets in reinvestment European CLOs.


Source: Kanerai, Intex, Markit, Barclays Research

With higher-rated assets repricing coupons lower and increasing loan downgrades, US CLO exposure to higher rated assets has declined. On average, US BSL CLO managers have lost almost 1 percentage point of Ba and higher assets and B1 assets since September 2019, while B2 through Caa buckets increased, on average, 0.2 to 0.6 percentage points (Figure 15). European CLOs saw a similar trend, although because average asset ratings are slightly lower in Europe, higher-rated asset exposure fell less, while B2 buckets declined on average by 1.8 percentage points (Figure 16).

FIGURE 15. US CLOs Have Seen a General Shift Lower in Asset Rating Buckets since September

Note: Only US CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020


Source: Kanerai, Intex, Barclays Research

FIGURE 16. Similar for European CLOs, Though with Greater Transition from B2 to B3 Buckets


Note: Only European CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020

Source: Kanerai, Intex, Barclays Research

Unlike the changes seen in asset spread buckets, only one of the tails drove most of the change in US BSL CLO WARF levels, with changes in exposure to Caa-rated assets the principal factor (Figure 17). For the top 25 managers by WARF performance (ie, WARF change was low or even negative), rating exposure deteriorated, but to a lesser extent than the rest of the sample, with Ba and B1 exposure declining 0.1-0.2 percentage points. Managers that underperformed on WARF change saw a much larger transition lower in rating buckets (Figure 18).


FIGURE 17. Lower-Rated Asset Buckets Drove Most of the Changes in US BSL CLO WARF Levels

Note: Only US CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanerai, Intex, Barclays Research


FIGURE 18. Managers That Outperformed on WARF Change Saw Lower-Rated Buckets Fill up Less

Note: Only US CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanerai, Intex, Barclays Research

Similar to the US, but to a lesser extent, changes in exposure to Caa-rated assets drove a majority of the change in European CLO WARFs (Figure 19). WARF performance for European CLO managers was more mixed, with similar trends for the top 10 managers that under- and outperformed (Figure 20). For the top 10 managers by WARF performance, ratings exposure deteriorated, but to a lesser extent than those that underperformed, with B2 exposure decreasing and B3 exposure increasing relatively less.

FIGURE 19. Similar to the US, Lower Rated Asset Buckets Drove Most of the Change in EU WARFs


Note: Only European CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanerai, Intex, Barclays Research

FIGURE 20. Managers That Underperformed on WARF Change Saw a Higher Transition from B2 to B3 Assets


Note: Only European CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanerai, Intex, Barclays Research

Looking Forward

As loan downgrade rates remained elevated in 2H19, we find that WARF test failure rates have begun to rise again, with US CLOs seeing a higher rate of failures (Figure 21). WAS test failure rates remain relatively low, though this could increase with more repricings, with rates around 2% in US CLOs and close to 0% in European CLOs (Figure 22).

FIGURE 21. US CLOs Have Been More Likely to Fail WARF Tests since Mid-2018

Note: Only US BSL CLOs in reinvestment.
Source: Kanerai, Intex, Barclays Research

FIGURE 22. European CLOs Have Seen Relatively Lower CQT Failure Rates

Note: Only European CLOs in reinvestment.
Source: Kanerai, Intex, Barclays Research

We believe this difference in WAS and WARF test failure rates could be due to managers being more willing to fail WARF tests, especially as loan downgrades have picked up. As we discussed in [A CLOser Look Inside the Matrix](#), CQT limits operate off a matrix, with the maximum WARF typically based on current minimum WAS and diversity score (DS) levels.

As average asset spreads have remained about flat, CLO managers have kept minimum WAS test limits relatively unchanged since the end of 2018. And while maximum WARF test limits have moved higher, the increase in limits is being outpaced by downgrades. Moody's notes that some CLOs have even purposefully worsened their WARF test failures to ensure they keep passing WAS tests, as having to find new assets that maintain or improve both a failing WARF and WAS test is becoming exceptionally difficult. The ability to perform this action is deal dependent, though, as some deals require that the tests cannot be failed further after a movement in the test limits.

We also find that average market CQT cushions can hide vintage effects. Nearly a third of 2017 vintage US BSL CLOs have 5bp or less of WAS cushion, compared with less than 10% for 2018 vintage deals ([Figure 23](#)). Deals issued in 2017 or earlier were most exposed to the last repricing wave and thus have had to be more nimble over time in replacing asset spreads. And despite diversity score (DS) levels having continually increased over the past few years, cushion for this test has remained tight as managers keep pushing for more diversification as a means to maintain passing levels of WAS and WARF tests.


FIGURE 23. CQT Cushion Differs Greatly by Vintage - Nearly a Third of 2017 Vintage US CLOs Have 5bp or Less WAS Test Cushion

	WAS				Moody's WARF				Diversity Score			
	US		EU		US		EU		US		EU	
Vintage	Fail	<=5bp	Fail	<=5bp	Fail	<=10p _t	Fail	<=10p _t	Fail	<=5pt	Fail	<=5pt
2014	1.4%	17.6%	0.0%	18.5%	7.0%	12.7%	0.0%	25.0%	2.9%	27.5%	0.0%	50.0%
2015	4.4%	14.7%	0.0%	27.8%	9.1%	13.6%	4.0%	4.0%	6.3%	38.1%	0.0%	54.2%
2016	4.9%	29.9%	0.0%	12.8%	13.7%	15.7%	0.0%	0.0%	8.0%	43.0%	0.0%	35.3%
2017	10.4%	33.3%	0.0%	20.0%	14.9%	14.9%	0.0%	0.0%	12.7%	44.0%	0.0%	47.4%
2018	6.9%	9.5%	2.2%	11.1%	18.4%	24.1%	6.7%	13.3%	7.7%	47.1%	0.0%	55.6%
2019	1.9%	9.6%	0.0%	13.3%	3.0%	6.0%	5.6%	9.7%	2.8%	27.3%	0.0%	41.7%


Note: Data show failure rate and how close deals are to a CQT failure. Only CLOs in reinvestment as of January 27, 2020.
Source: Kanerai, Intex, Barclays Research

Should we see repricings cut 10bp on average from CLO WAS and loan downgrades continue, we could obviously see more test failures, especially for vintages that have very little cushion today. But to simply take 10bp off the average WAS test cushion would likely overstate a projected failure rate since CLO managers have several avenues to prevent such failures.

Even managers with relatively lower WAS levels can still maintain WAS test cushion decline at a similar rate to high spread managers, as we have seen since September 2019 (Figure 24). It is a similar case for high and low WARF managers, for whom WARF test cushion declines were similar over the same period (Figure 25). Thus, we think CQT failure will depend more on vintage and manager than starting portfolio composition.

FIGURE 24. Starting WAS Gives Little Insight into Deals That Ultimately Lose WAS Test Cushion

Note: Only US CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanerai, Intex, Barclays Research


FIGURE 25. Similarly, Starting WARF Levels Provide Few Clues to Deals That Lost Cushion

Note: Only US CLO managers in sample. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanerai, Intex, Barclays Research

Regardless, a majority of CLOs will have to de-risk if WAS declines more than expected as repricings increase and WARFs creep higher as downgrade rates rise. Managers have different options to achieve this, such as shifting to a slightly more conservative portfolio, but some managers may instead choose to increase tail risk in order to keep passing such tests.


In the US, we found that some deals have continued to add risk even though test cushions are relatively low (Figure 26). For example, some deals have continued to add exposure to high spread assets (more than 450bp spreads) since September 1, even though WAS test cushions at the start of the period were relatively low (5bp or less). But similar to the European CLO data (Figure 27), the dispersion across managers is high, with some deals choosing not to add tail risk in order to stay onside of CQTs.

FIGURE 26. Some US CLOs Continued Adding High Spread Assets Even as WAS Test Cushions Remained Tight



Note: Only US BSL CLOs with test data available. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanerai, Intex, Barclays Research

FIGURE 27. Similar for European CLOs, but Results Are Still Mixed



Note: Only European CLOs with test data available. Change from latest Intex updates as of September 1, 2019, and January 27, 2020.
Source: Kanerai, Intex, Barclays Research

Thus, while it is difficult to predict which types of deals and managers are most susceptible to failing a CQT (outside of specific vintages with less cushion to begin with), we still recommend that investors analyze how managers are dealing with CQTs and how the portfolio is shifting as a result.

Each research report excerpted herein was certified under SEC Regulation AC by the analyst primarily responsible for such report as follows: I hereby certify that: 1) the views expressed in this research report accurately reflect my personal views about any or all of the subject securities referred to in this report and; 2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

Important Disclosures:

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242. Barclays trades the securities covered in this report for its own account and on a discretionary basis on behalf of certain clients. Such trading interests may be contrary to the recommendations offered in this report.

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, “Barclays”).

All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

Availability of Disclosures:

For current important disclosures regarding any issuers which are the subject of this research report please refer to

<https://publicresearch.barclays.com> or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays may have a conflict of interest that could affect the objectivity of this report. Barclays Capital Inc. and/or one of its affiliates regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). Barclays trading desks may have either a long and / or short position in such securities, other financial instruments and / or derivatives, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, Barclays fixed income research analysts regularly interact with its trading desk personnel regarding current market conditions and prices. Barclays fixed income research analysts receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the Investment Banking Department), the profitability and revenues of the Markets business and the potential interest of the firm’s investing clients in research with respect to the asset class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not necessarily represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations and trade ideas contained in one type of Barclays Research may differ from those contained in other types of Barclays Research, whether as a result of differing time horizons, methodologies, or otherwise.

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to

<https://publicresearch.barcap.com/S/RD.htm>. In order to access Barclays Research Conflict Management Policy Statement, please refer to: <https://publicresearch.barcap.com/S/CM.htm>.

Includes content supplied by IHS Global Inc. and its affiliates (“IHS”) [2020]. The use of this content was authorized in advance by IHS. Any further use or redistribution of this content is strictly prohibited without written permission by IHS. All rights reserved.

All pricing information is indicative only. Unless otherwise indicated, prices are sourced from Refinitiv and reflect the closing price in the relevant trading market, which may not be the last available price at the time of publication.

Types of investment recommendations produced by Barclays FICC Research:

In addition to any ratings assigned under Barclays’ formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts in FICC Research. Any such investment recommendations produced by non-Credit Research teams shall remain open until they are subsequently amended, rebalanced or closed in a future research report. Any such investment recommendations produced by the Credit Research teams are valid at current market conditions and may not be otherwise relied upon.

Disclosure of other investment recommendations produced by Barclays FICC Research:

Barclays FICC Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays FICC Research in the preceding 12 months please refer to <https://live.barcap.com/go/research/Recommendations>.

Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Bank Ireland PLC, Frankfurt Branch (BBI, Frankfurt)

Barclays Bank Ireland PLC, Paris Branch (BBI, Paris)

Barclays Bank Ireland PLC, Milan Branch (BBI, Milan)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India branch (Barclays Bank, India)

Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)

Barclays Bank PLC, DIFC Branch (Barclays Bank, DIFC)

Disclaimer:

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, “Barclays”). It has been prepared for institutional investors and not for retail investors. It has been distributed by one or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an “institutional debt research report” and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from republishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact debtresearch@barclays.com. Clients that are subscribed to receive equity research reports, will not receive certain cross asset research reports co-authored by equity and FICC research analysts that are distributed as “institutional debt research reports” unless they have agreed to accept such reports. Eligible clients may get access to such cross asset reports by contacting debtresearch@barclays.com. Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site (“Third-Party Content”). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results. The information provided does not constitute a financial benchmark and should not be used as a submission or contribution of input data for the purposes of determining a financial benchmark.

United Kingdom: This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being “Relevant Persons”). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

European Economic Area (“EEA”): This material is being distributed in the EEA by Barclays Bank PLC. Barclays Bank PLC is not registered in France with the Autorité des marchés financiers or the Autorité de contrôle prudentiel.

Americas: The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund (CIPF).

This material is distributed in Mexico by Barclays Bank Mexico, S.A. This material is distributed in the Cayman Islands and in the Bahamas by Barclays Capital Inc., which it is not licensed or registered to conduct and does not conduct business in, from or within those jurisdictions and has not filed this material with any regulatory body in those jurisdictions.

Japan: This material is being distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143.

Asia Pacific (excluding Japan): Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 2267196000. Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INBI00000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this material, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by Barclays Bank PLC. None of Barclays Bank PLC, nor any other Barclays group entity, holds an Australian financial services licence and instead relies on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001. This material is distributed in New Zealand by Barclays Bank PLC, but it has not been registered, filed or approved by any New Zealand regulatory authority or under or in accordance with the Financial Markets Conduct Act of 2013, and this material is not a disclosure document under New Zealand law.

Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

This material is distributed in the United Arab Emirates (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC. Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority. Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi). This material does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe for or purchase, any securities or investment products in the UAE (including the Dubai International Financial Centre) and accordingly should not be construed as such. Furthermore, this information is being made available on the basis that the recipient acknowledges and understands that the entities and securities to which it may relate have not been approved, licensed by or registered with the UAE Central Bank, the Dubai Financial Services Authority or any other relevant licensing authority or governmental agency in the UAE. The content of this report has not been approved by or filed with the UAE Central Bank or Dubai Financial Services Authority. Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2020). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.

BRCF2242